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Abstract
Background: Immunological and cytological examination of bronchoalveolar lavage (BAL) fluid
is frequently used for diagnostics and research of interstitial lung diseases (ILD). Flow cytometry (FC)
is a common tool applied to investigations on biology of alveolar lymphocytes (AL). However, there is
no consensus on the processing of immunophenotyping of BAL samples. As a consequence, the normal
values of AL subsets are not definitely established.
The aim of the study was to determine the normal phenotype values of AL, using precise inclusion
criteria in a relatively large cohort of healthy individuals. The data generated in this way could serve
as a reference point for investigations and diagnostics of lower airways. 
Material and methods: AL were obtained from BAL performed in 41 individuals free of any lung
pathology, incl. 27 nonsmokers, NS, and 14 smokers, S. Direct double- and three-colour
immunophenotyping was used for analysis of AL subsets, as well as for the markers of their activation
and apoptosis susceptibility. Precise criteria of flow cytometry acquisition and analysis were employed.
Mean fluorescence intensity (MFI) was determined for major AL subsets. The parallel typing of peripheral
blood lymphocytes (PBL) was carried out. 
Results: Both in NS and S, alveolar lymphocytes were almost exclusively T cells (90.1±1.4% and
89.3±1.6% respectively, median ± SEM). B and NK cells in BAL fluid occurred infrequently (2.7±0.4
and 4.2±0.8% in NS, 2.6±0.9 and 3.6±0.9% in S, respectively), as compared to peripheral lymphocytes
(10.1±1.2% and 9.3±1.7% in NS, 17.9±3.4% and 14.0±1.9% in S, respectively, p<0.0001 for both).
The AL were mostly CD45R0+ and CD95+ cells, regardless of analyzed subset (CD4 or CD8) and
smoking status. Low BAL CD4/CD8 ratio in smokers, due to increased percentage of CD8+lymphocytes
presenting T cytotoxic cell phenotype (CD8+CD11b–) was found (39.9±4.4% vs. 21.8±2.7% in NS,
p<0.01). Only some AL CD8+ expressed suppressor cell phenotype (CD8+CD11b+), in opposite to the
results obtained from peripheral blood. BAL fluid recovery (high value reflects increased content of
alveolar cells vs. bronchial contamination) in NS (but not in S) was positively correlated with percentage
of AL CD4+ (R Spearman +0.46, p=0.04) and CD4/CD8 ratio (R Spearman +0.45, p=0.02). MFI of
CD3 and CD4 superficial antigens was significantly decreased on AL as compared to PBL (p<0.001
and p<0.01 resp.).
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Introduction
In the past ten years, the authors used flow cytometry
(FC) in order to test more than 500 BAL materials
originating from patients suspected of interstitial lung
diseases (ILD). BAL, including alveolar lymphocyte (AL)
typing, is considered as an important diagnostic tool in ILD
patients, as in sarcoidosis, hypersensitivity pneumonitis,
transplant recepients and many others [1-6]. Moreover, the
investigations on pathogenesis of ILD, as well as of
bronchial asthma, lead to conclusions emphasizing the
principal role of lower airways lymphocytes in lung
pathology. In the studies concerning the subject, lymphocyte
phenotype and function were largely discussed [7-10]. 
However, in the papers published by other authors we
encountered the problem of reference values for AL
phenotypes. The difficulties could be summarized as follows: 
1. The technical problems related to FC analysis of alveolar
lymphocytes involve: 
a) AL are different in shape as compared to PBL, so
special gating procedures are discussed [11, 12]; 
b) AL flow cytometric gate is commonly contaminated
by large red cells and monocytic forms of alveolar
macrophages (AM) [13]; 
c) antigen sharing between AL and AM occurs [11]; 
d) poor lymphocytic materials (as for example in healthy
smokers) are difficult to be analyzed; a double-colour
FC analysis is often insufficient then [12, 14]; 
e) results calculated from BAL material (in this number
cytology and cell phenotype data) present
nonparametric distribution of variables and a wide
range of values [15]. 
2. The control groups collected for different research
purposes are not numerous enough, if to take into account
the technical complications listed in the point 1. For
example, the nonparametric distribution of data could be
avoided in part by collecting the numerous group of
healthy individuals, but this condition is difficult to
accomplish [2, 11, 14, 16, 17]. 
3. Any BAL used for ILD diagnostics needs a reference
point, i.e. especially numerous and carefully yielded
control group of AL collected in the respective center
[2]. There is a remarkable necessity to elaborate basic
principles of BAL material sampling and AL subset
analysis, parallel to PBL processing. Additionally, the
absence of uniformity in lymphocyte typing of BAL fluid
has made comparisons between various reports difficult
or even impossible [18]. 
4. Controls should be collected separately for nonsmoker
and smoker group, due to the distinct cytoimmunological
pattern observed in the latter. These fundamental
conditions are not always exactly fulfilled [19-21]. It
should be remember, that in healthy nonsmokers,
lymphocytes constitute about 10% (or even more) of
reactive cells obtained from lungs by BAL procedure.
The respective value in smokers is about 5%; the
majority of rest alveolar cells are macrophages [22]. This
cytological pattern seems to be physiological.
5. Up to now, the role of alveolar lymphocytes in the local
immunity has not yet been fully understood. Some
investigators consider that AL simply reflect the
inflammatory process in the surrounding interstitium [19,
23]. Some others, however, accentuate the biased (i.e.
preferential) accumulation of T lymphocytes on the
surface of lower airways [24]. These differences
implicate the way, that the authors interpret their results.
6. There is no consensus on some other important
phenotypic and functional features of alveolar
lymphocytes, including so basic parameters as proportions
of T, B and NK cells. It is also unclear, if apoptosis occurs
frequently in AL population and if AL proliferate in the
alveoli. The studies reporting the lymphocyte migration
from lower airways back to the local lymphatic nodes also
need confirmation [17, 25-28]. 
In the current study we presented the particular
characteristics of AL phenotypes, examined with use of FC.
The material, obtained from the relatively large group of
healthy individuals, has been collected by our team for
several years. The attention was focused on AL harvested
on physiological conditions, i.e. from nonsmoking subjects
free of any lung pathology. Additionally, the group of
“healthy” smokers was established, as sine qua non for all
diagnostic and research BAL procedures concerning the
smoking patients. The results of nonsmokers and smokers
were presented separately. The smoker control group was
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Conclusions: The normal value range was proposed for BAL lymphocyte immunophenotyping. The
results support the hypothesis that T cells as a major subset of AL, they are chronically stimulated in
lungs by specific antigens and carry the phenotype of primed memory/effector cells. Helper T cells are
the lymphocytes that accumulate preferentially in alveoli in physiological conditions.
Key words: alveolar lymphocytes, bronchoalveolar lavage, flow cytometry, lymphocyte subsets, mean
fluorescence intensity
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not numerous enough to constitute the normal value range
of AL phenotypes.
The careful, standardized BAL fluid collection and FC
evaluation of AL was proposed as the optimal solution for
troubles mentioned above. Furthermore, the BAL fluid
recovery was used as an important indicator of pure alveolar
space content versus bronchial contamination. The mean
fluorescence intensity (MFI) assessment was included. The
parameters tested in the study were selected in order to
better understand the role of alveolar lymphocytes (and their
subsets) in the local immunity. 
The purposes of the study were: 
1) to propose the normal value range of AL for further
diagnostics and research investigations;
2) to characterize the phenotype of normal alveolar
lymphocytes obtained by bronchoalveolar lavage (BAL); 




The studied group consisted of 41 individuals who
underwent bronchoscopy for diagnostic reasons and were
retrospectively free of any infectious, inflammatory or
malignant lung disease. Microbiological analysis of the BAL
fluid was negative for bacteria, mycobacteria and fungi.
Complete clinical investigation (incl. chest X-rays, lung
function tests, DLCO and arterial blood gas analysis)
definitely excluded presence of any lung pathology. No
subjects were treated with corticosteroids, immunosuppresive
therapy or any other drugs known as a potential cause of ILD
(nitrofurantoin, amiodaron, PAS, etc.). 
The characteristics of the control population are
summarized in table 1.
The Bioethical Commission of Collegium Medicum,
University of Nicolaus Copernicus, Bydgoszcz, gave the
permission (no KB/294/2003) for the study.
Table 1. Nonsmokers and smokers – BAL cytology




sex M/F 10/15 11/3 ns
smoking history* no of pack-years** - 16.1±13.3
(2-42)
BAL fluid recovery % 60±3 54±3
(36-75) (34-70) ns
total BAL cell no cells x 103/ ml 197±30 495±55
(55-310) (187-780) <0.01
alveolar macrophages (AM) % 87.0±1.3 92.9±0.9
(60.6-96) (86.1-97.1) <0.01
alveolar lymphocytes (AL) % 11.8±1.3 5.6±0.6
(3.0-37.8) (2.5-10.1) <0.001
neutrophils % 1.3±0.2 1.4±0.3
(0-4) (0.3-3.3) ns
eosinophils % 0.3±0.06 0.3±0.08
(0-1.3) (0-0.8) ns
mast cells % 0.5±0.1 0.7±0.2
(0-0.8) (0-1.0) ns
*  mean ± SD; all other data were presented as mean ± SEM (range) 
**  number of packs smoked per day times number of years smoked (data collected from 12 individuals)
ns – non significant (U Mann-Whitney test) 
Central European Journal of Immunology 2004; 29(3-4)66
Piotr Kopiñski et al.
Bronchoalveolar lavage performance
BAL was carried out, as previously described [10, 16].
In brief, midazolam 2.5-5.0 mg IV, followed by local
anesthesia with 2% lidocaine solution was used for
premedication. The Olympus Bf 20 bronchofiberoscope was
introduced to the middle lobe or to the left lung lingula,
alternatively. Lavage with 200 ml of 0.9% NaCl sterile
solution (37oC) was carried out by sequential instillation of
four 50 ml aliquots of saline. The BAL fluid fractions were
retrieved carefully by gentle suction, then pooled and
filtered. The fluid recovery was calculated as the percentage
of instilled volume [29]. The material was send to the
laboratory and cytoimmunological examination was
undertaken without delay (as for flow cytometry, average
time from BAL collection to the beginning of staining was
45 minutes). 
BAL fluid cytology
BAL cell fluid viability determined by trypan blue
exclusion test was >90% in all samples. Total cell number
was calculated and aliquots of 100-300 ul fluid were
cytocentrifuged (Cytospin Shandon 3, 1500 r.p.m./min, 5
min.). Cytospin preparations were stained simultaneously
with hematoxylin-eosin (HE) and May-Grünwald-Giemsa
(MGG). The differential count of BAL fluid reactive cells
was calculated in each case as the average value of both
preparations (at least 500 cells were counted) [12]. For mast
cells, toluidine blue staining was applied, as previously
described [30].
AL subsets phenotyping 
BAL material was centrifuged (300 g, 10 min.) and a
cell pellet was resuspended with PBS to 2-10 x 106 cells per
ml. The samples containing 50 ul of cell suspension were
incubated with mixture of saturating amounts (5-10 ul
usually) of monoclonal antibodies for 30 minutes in dark.
Double- or three-colour typing was performed, according
to the percentage of AL (more or less than 5% of BAL fluid
reactive cells, respectively). Mouse anti-human monoclonal
antibodies (Becton Dickinson Immunocytometry Systems,
Mountain View, CA, USA) used in the study, were listed in
the table 2. For three-colour immunostaining, anti-CD45
PECy5 (DAKO A/S, Glostrup, Denmark, 5 ul per sample)
was given additionally. Negative isotype control was used
for each sample series. After incubation, cells were washed
with PBS (300 g, 10 min.) and resuspended in 300 uL of
PBS containing 1% formaldehyde [12, 21]. 
Parallel PBL typing was performed due to BD Simultest
IMK protocol. In brief, heparinized peripheral blood was
Table 2. Al (alveolar lymphocyte) phenotype staining. Monoclonal antibodies (MoAb) used for direct immunofluorescence 
Sample FL 1 FL 2
no MoAb  FITC MoAb PE Notes
Conjugated Conjugated
1 CD45* / BAL lymphocyte gate defining 
2 CD15* CD14* granulocyte/macrophage contamination in AL gate  
3 CD3 CD19 T&B cells
4 CD4* CD8 CD4/CD8 ratio
5 CD3 HLA-DR* activated T cells ("late" activation marker)
6 CD3 CD16* + CD56 T&NK cells 
7 CD25* CD4* activated Th cells ("early" activation marker)
8** CD95* CD4* (CD8) marker of cells (Th/Tc) susceptible to apoptosis (Fas)
9** CD178* CD4* (CD8) marker of cells (Th/Tc) inducing apoptosis (Fas Ligand)
10 CD45RO* CD4* (CD8) primed memory cells (Th/Tc)
11 CD19 CD5* B cell subsets
12 CD8 CD11b* Tc&Ts cells 
13 control antibody (IgG 1) control antibody (IgG 2a) negative isotype control  
*  antigen sharing with alveolar macrophages  
** n=13 
Mouse anti-human CD45 PECy5 (for three-colour AL analysis) was applied to samples 2-7, 10-13. 
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incubated with monoclonal antibodies; hemolysis with BD
Lysing Solution was performed subsequently. Next steps
were carried out according to AL staining procedure. 
AL flow cytometry analysis 
FC data were acquired within 24 hours after staining,
using CellFit software and FACSCalibure cytometer (BD
Immunocytometry Systems). An argon ion laser was used
for 488 nm excitation. Emitted light was detected by
logarithmic amplification through barrier filters specific for
the emission range of the different fluorophores: 530/22 nm
for FITC (fluorescence channel FL1), 585/42 nm (FL2) for
PE and >650 nm (FL3) for PE Cy5. From each sample
8000-12000 events (cells) were acquired. 
AL gate was determined due to the cell granularity
(SSC, side scatter) and intensity of staining with CD45
FITC (“back gating”). The gated cells were assessed by
quadrant analysis of FL1 vs FL2 channel dot plot. Results
were presented as the percentage of all gated lymphocytes
[31]. Mean fluorescence intensity (MFI) was calculated for
CD3, CD4, CD5, CD8 and CD45. Arbitrary units were
used, according to the reference [32]. We resigned to assess
MFI for B and NK cell markers, because these subsets of
AL were sparse or absent. 
Phenotype and MFI data were calculated with PC-Lysys
software. Criteria for correct FC analysis of AL were listed
in the table 2 (they were commented on elsewhere) [12, 14].
Materials, which failed to fulfill these criteria, were not
included in the study. 
Statistics
All BAL cytology and phenotype results were presented
as median ± SEM (due to nonparametric distribution of
values, see introduction). The Mann-Whitney U test to
compare the obtained data (NS vs S) and paired Student’s
test to analyze pairs of values (AL vs PBL) were used. The
Spearman’s rank correlation coefficient rs was applied to
test for correlation between two random variables. P-values
less than 0.05 were considered statistically significant. 
Results
Results of BAL fluid cytology were shown in the table
1. Significant increase in total cell number and AM
percentage, as well as significant decrease in AL percentage
was found in smokers, as compared with nonsmoker group. 
AL phenotype results were compared to PBL and
presented in the figures 1-2 and the table 4. In both,
nonsmokers and smokers, AL were dominated by T cells
with only few B and NK cells. In each individual case, BAL
fluid CD3+ and CD5+ percentage was higher than
respective PBL data; percentage of alveolar B cells (CD19+)
and NK cells (CD3–CD[16+56]+) was lower (fig. 1). 
AL and PBL CD4/CD8 results were presented in the fig.
2: the CD4/CD8 ratio decreased significantly in smokers,
as compared to nonsmokers (0.94±0.37 vs. 1.87±0.21,
p<0.001). On the contrary, PBL CD4/CD8 ratio was higher
in smokers (2.04±0.18 vs. 1.32±0.1, p<0.05).  
BAL fluid obtained from smokers was characterized by
significant decrease in CD4+ and CD5+CD19+ cell
percentage, as well as elevated proportion of CD8+ and
CD8+CD11b– (phenotype of Tc) cells. 
The majority of both CD4 and CD8 cells in BAL fluid,
in opposite to PBL parallel results, were CD45R0+
(phenotype of primed memory cells) and CD95+, i.e. Fas+
(up to 100% alveolar T cells seem to be susceptible to
membrane pathway of apoptosis induction). These data were
presented in brief in the table 4, without further distinction
to CD4 and CD8 cells. Fas Ligand (CD178) was expressed
more frequently in AL than in PBL, and the percentage of
CD8+CD178+ cells was increased in BAL fluid of S, as
compared with NS (p<0.05). 
No differences in expression of activation markers
between tested groups were found. 
MFI of CD3+ and CD4+ cells was significantly lower
in BAL fluid, as compared with PBL, both in nonsmokers
(101±2.2 vs 120±1.9, p<0.001, and 91±10.7 vs 111±7.4,
p<0.01 mean ± SEM, resp.) and in smokers (96±11 vs
116±12.4, p<0.001, and 94±17.9 vs 109±21, p<0.01).
Remarkable decline in MFI of CD3 and CD4 antigens
assessed on AL surface was observed in all examined
subjects, as compared to PBL. No changes in MFI of other
lymphocyte markers were found. 
Table 3. Criteria of FC analysis – alveolar lymphocyte
phenotypes
Criterion Accepted  
value 
epithelial cells in BAL material <3%* 
lymphocytes in BAL material >10000
lymphocytes in a single sample  >500
total AL percent (CD45/SSC) in lymphocytic gate  >95%
AM contamination in AL gate <4%
granulocyte contamination in AL gate <4%
all contamination together (AM, granulocytes, <40%
red cells, debris)
T+B+NK cells >90%
CD3+ percentages in different samples of the same <5%
patient - difference of separate results  
Criteria based on the references for PBL immunotyping, modified for AL subset
[12, 14, 31]
* In all BAL materials involved in the study we obtained <1% of epithelial cells
(calculated as percentage of all cells) 
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In nonsmokers BAL fluid recovery was positively
correlated with AL CD4+ percentage (rs +0.46, p=0.04),
and inversely with AL CD8+ (rs –0.36, p=0.09; fig. 3). It
finally resulted in BAL fluid recovery significant positive
correlation with AL CD4/CD8 ratio (rs +0.45, p=0.02).
Additionally, CD4+CD25+ subset percentage and BAL
eosinophil percentage was correlated negatively with fluid
recovery (rs –0.67, p=0.03 and rs –0.77, p=0.01,
respectively) in smokers. 
The example of FC analysis of AL subsets was
presented in the fig. 4.
In the table 5 we proposed the normal value range of
major alveolar lymphocyte subsets in healthy nonsmokers.
It could serve as the baseline for future studies and
diagnostics, which will include AL typing.
Discussion
The first studies describing AL as a separate lymphocyte
population were published in the late 80’s and early 90’s
[11, 16, 33]. Initially, many authors did not find important
differences between AL and PBL in distribution of main
lymphocyte subsets: they reported relatively low percentage
of T cells in BAL in these studies, and the proportions of
BAL B or NK cells were similar to those found in peripheral
blood [14, 16, 19, 22]. Additionally, there was no consensus
on the flow cytometric criteria of AL gating and subset
analysis, in contrast to the precise guidelines established for
PBL [18]. 
In the current study, the standardized method of AL
immunophenotyping resulted in the observations described
above. The attention should be paid to the fact that in each
evaluated subject, the sum of T+B+NK cell percentage
(indicator of correct FC analysis, see table 3) was over 90%
(and usually more than 95%) [31]. 
It should be regarded as a rule that BAL fluid of every
healthy individual contains higher proportion of T cells with
corresponding decrease in percentage of B and NK cells,
as compared to peripheral blood. It did not matter, which
particular CD antigen (CD3 or CD5) was used for T cell
detection. Data presented here were in general consistent
with findings of other researchers. However, some authors
reported relatively high values of NK and/or B cells in BAL
fluid [16, 34]. In the current study we defined NK cells with
Piotr Kopiñski et al.
Fig. 2. Main subsets of BAL (AL) and blood (PBL) lymphocytes: T, B and NK cells. Data from nonsmokers and smokers were pooled
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Table 4. AL & PBL subsets – comparison
Parameter Nonsmokers Smokers
[%] [%] P
AL CD4+ 51.4±2.8 (34-78) 43.1±3.2 (23-56.8) <0.01
CD4+CD25+/CD4+ * 9.7±1.5 (0-22.2) 12.8±1.3 (0.6-16.7) ns
CD8+ 30.5±2.1 (19.1-58) 46.5±2.6 (33.9-60.0) <0.001
CD8+CD11b-/CD8+ * 88.5±1.8 (85-93) 94.4±1.4 (92-97) <0.05
CD5+CD19+ 1.5±0.3 (0-3.8) 0.5±0.2 (0-1.4) <0.001
CD45R0 + ** 85.1±5.3 (68-99) 81.6±7.2 (70-95) ns
CD95+ ** 89.4±2.9 (73-96) 77.4±5.2 (56-100) ns
CD4+CD178+ 5.0±2.4 (1.9-17) 5.3±2.2 (2.1-10) ns
CD8+CD178+ 2.3±0.7 (1.5 -6) 8.3±3.2 (1.9-13) <0.05
PBL CD4+ 40.0±1.4 (24.4-51) 49.0±1.9 (40.7-59.3) <0.001
CD4+CD25+/CD4+ * 5.1±0.9 (1.3-15.9) 7.1±1.3 (0.7-16.3) ns
CD8+ 32.0±1.2 (23.9-44) 24.9±1.4 (17-33.1) <0.01
CD8+CD11b-/CD8+ * 47.2±1.6 (12.3-55.9) 33.8±1.3 (11.3-48.6) ns
CD5+CD19+ 1.9±0.3 (0.5-4.3) 1.9±0.4 (0.5-5.0) ns
CD45R0 + ** 47.0±3.2 (33-55) 42.4±5.1 (36-59) ns
CD95+ ** 32±7.2 (3-42) 31.5±13 (13-44) ns
CD4+CD178+ 1.4±0.4 (0.5-3.5) 0.6±0.2 (0-3.5) ns
CD8+CD178+ 3±0.7 (0.3-5.4) 0.6±0.3 (0.2-3.3) ns
All results were presented as median ± SEM (range)
* results presented as percentage of CD4+ (CD8+) cells (respectively); all other results presented as proportion of total AL
** data shown in brief, for total AL only; 
ns – non significant 
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Fig. 3. Nonsmokers. Correlation between AL subsets (CD4, CD8) and BAL fluid recovery
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Fig. 4. AL analysis in FC – example 
Table 5. AL subsets of nonsmokers (NS) – proposal of normal value range
Subset Median ± SEM % Critical Range* % Comments 
T cells CD3+ 90.1±1.4 76-95 more than in parallel peripheral blood staining
B cells CD19+ 2.7±0.4 0-6 less than in parallel peripheral blood staining
NK cells 
CD3-(CD16+56)+ 4.2±0.8 0-10 less than in parallel peripheral blood staining








CD5+CD19- 90.0±2.3 74-96 more than in parallel peripheral blood staining
* the column contains the values between 5 and 95 percentyl; 
higher or lower results indicate pathology or inapropriate BAL material processing
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use of monoclonal antibodies (CD3 FITC/CD[16+56] PE)
excluding any antigen sharing with T cells. Results obtained
in this way confirmed view on the minimal role of NK cells
in lung local immunity [25], both in nonsmokers and
smokers. 
Low MFI value of CD3 and CD4 on alveolar
lymphocytes, observed in ILD by other authors [7, 8, 17],
seems to reflect local chronic antigen stimulation of AL. In
this study, similar results (low CD3 and CD4 MFI) were
also observed in healthy individuals. 
In practice, low MFI of CD3+CD4+ cells in BAL fluid
results in underestimation of proportion of CD3+ cells, sum
of T+B+NK cells and CD4/CD8 ratio. For this reason, flow
cytometry should be used preferably in processing of BAL
material, including AL typing; the immunoenzymatic
techniques (as immunoperoxidase staining) should be
avoided [12]. 
Summing up, the flow cytometric characteristics of AL
subsets established in the current study supports the
hypothesis on biased T cell accumulation on the surface of
pulmonary alveoli [24, 25]. Moreover, our results suggest
that in nonsmokers the accumulation concerns mostly CD4+
T cells (T helpers). The crucial role of lung Th cells in the
local immune defense is largely discussed in the literature
[8, 17, 26, 34]. For instance, they could be stimulated by
contact with dendritic and other antigen presenting cells
[35]. They can be also active as cytotoxic cells [12]. In our
material, the CD4/CD8 ratio in BAL fluid of nonsmokers
was significantly higher than respective PBL value.   
The decreased CD4/CD8 ratio in BAL fluid of smokers,
referred by many authors [6, 21, 36], was completed by our
observation of local predominance of T cells which express
cytotoxic (but not suppressor) phenotype. We did not find
any increase in number of neutrophils in smokers, reported
by some authors [21, 22]. Relatively increased proportion
of BAL eosinophils in smoking subjects constituted the
contamination of upper airways, since this parameter was
significantly and negatively correlated with BAL fluid
recovery. 
Interleukin-2 receptor (CD25), commonly applied as a
marker of AL activation, should not be recommended. The
number of BAL CD4+CD25+ lymphocytes was negatively
correlated with fluid recovery in nonsmokers. It means that
CD25+ cells originate partially from the upper airways.
The majority of AL, both Th and Tc, were positive for
CD95. This finding reflected high AL susceptibility to
membrane proapoptotic stimuli [27]. Paradoxically,
lymphocyte apoptosis is not a common event in BAL
material [10]. Fas Ligand (CD178) positive lymphocytes
are relatively rare in BAL material; the remarkable increase
in proportion of CD8+CD178+ cells in healthy smokers
needs further investigation.
Conclusions 
1. The normal value range of major subsets of alveolar
lymphocytes was proposed for healthy nonsmokers. It
was based on standardized approach to flow cytometric
analysis of BAL material collected in a relatively large
group of people. 
2. Alveolar lymphocytes in the control group, both in
nonsmokers and smokers, are dominated by T cell subset.
B and NK cells occur infrequently in BAL fluid, as
compared to PBL. 
3. BAL fluid recovery in nonsmokers is positively correlated
with BAL CD4/CD8 ratio. 
4. Mean fluorescence intensity of CD3 and CD4 superficial
antigens is significantly decreased on AL as compared to
parallel PBL staining.
5. The results support the hypothesis that T cells as a major
subset of AL, they are chronically stimulated in lungs by
specific antigens and carry the phenotype of primed
memory/effector cells. Helper T cells are the lymphocytes
that accumulate preferentially in alveoli in physiological
conditions. 
The study was supported by the grant of State
Committee for Scientific Research no 3P05D 15322.
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